Sutro Biopharma stock analysis
Sutro Biopharma (S090) Stock Price & Analysis
S090 Stock Chart & Stats
- Day’s Range
- EUR 11.50 - EUR 11.50
- 52-Week Range
- EUR 6.53 - EUR 36.00
- Previous Close
- EUR 11.50
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 134.69M
- Enterprise Value
- EUR 384.00M
- Total Cash (Recent Filing)
- EUR 142.18M
- Total Debt (Recent Filing)
- EUR 259.01M
- Price to Earnings (P/E)
- ―
- Beta
- 1.32
- Next Earnings
- Mar 29, 2027 (Est.)
- EPS Estimate
- -1.32
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
High Gross Margin
The approximately 97% TTM gross margin shows that Sutro’s underlying partnered and development-related economics can be attractive before operating expenses. If the company advances programs toward commercialization or expands collaboration activity, this margin profile could support meaningful operating leverage.
Advancing Clinical Pipeline
Rapidly moving multiple ADC programs into clinical testing strengthens the company’s development platform and creates several potential value drivers. A broader pipeline can improve the odds that clinical progress, partnering activity, or future approvals offset setbacks in individual programs.
Strategic Partner Execution
Astellas beginning patient dosing with another partnered ADC provides evidence that Sutro’s platform is being used beyond its wholly controlled pipeline. Continued partner execution can fund development, broaden validation of the technology, and create milestone or royalty opportunities over time.
Bears Say
Deteriorating Revenue Trend
The sharp TTM revenue decline indicates that collaboration and milestone-related revenue remains inconsistent rather than steadily compounding. Because Sutro depends largely on partner payments and development arrangements, weaker or delayed activity can prolong losses and make funding needs harder to plan.
Persistent Cash Burn
Operating and free cash outflows of roughly $129 million show that Sutro is consuming substantial cash to fund its operations and clinical pipeline. Persistent burn increases dependence on external capital, potentially limiting strategic flexibility and creating dilution or financing pressure.
Negative Stockholders’ Equity
Negative equity reflects the cumulative effect of losses and weakens the balance sheet’s financial flexibility even though headline debt is modest. This condition can make future capital raising more important and may constrain the company’s ability to absorb setbacks while funding clinical development.
S090 FAQ
What was Sutro Biopharma’s price range in the past 12 months?
What is Sutro Biopharma’s market cap?
When is Sutro Biopharma’s upcoming earnings report date?
How were Sutro Biopharma’s earnings last quarter?
Is Sutro Biopharma overvalued?
Does Sutro Biopharma pay dividends?
What is Sutro Biopharma’s EPS estimate?
How many shares outstanding does Sutro Biopharma have?
What happened to Sutro Biopharma’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Sutro Biopharma?
What is the TipRanks Smart Score and how is it calculated?
Sutro Biopharma Stock Smart Score
Company Description
Sutro Biopharma
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jane Chung
- Employees
- 129
- Website
- www.sutrobio.com
- Address
- 111 Oyster Point Boulevard, South San Francisco, CA, 94080, US
Sutro Biopharma (S090) Earnings & Revenues
S090 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 2 | 13 |
| Technical Analysis | 2 | 2 | 2 |
| Moving Averages | 1 | 0 | 11 |










